Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R.1672 - Maintaining Investments in New Innovation Act.
2025 · 2nd Quarter (Apr 1 - June 30)
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS)
Filed by TIBER CREEK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 21, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK GROUP
- Filing UUID
- b0d5155e-3faa-43bb-bbab-94760d0c2f3b
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to PBM reform; Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to 340B Drug Pricing Program; General Intellectual property issues; Issues related to pharmacy benefit managers.
Issues related to tariff policy and supply chain policy.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.